Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the appointment of experienced biotechnology industry executive, Christophe Quéva, Ph.D, as Chief Executive Officer (CEO). With over 20 years of experience in the biotechnology industry, Dr. Quéva brings a wealth of expertise as Egle transitions into the clinic its two lead drug candidates, EGL-001 and EGL-003.

“I am thrilled to join Egle Therapeutics and collaborate with a team renowned for its deep scientific expertise in regulatory T cells and its strong track record in developing innovative drug candidates for immunology and oncology” said Christophe Quéva, Ph.D. “Egle is uniquely positioned to demonstrate the therapeutic potential of harnessing regulatory T cells for treating both cancer and autoimmune diseases.”

“As we transition from a company with preclinical assets to a fully-fledged clinical-stage biotech, we will benefit greatly from Christophe’s deep operational and strategic expertise. We are delighted to welcome Christophe to the Egle team and look forward to the successes he will drive.” said Vincent Brichard, M.D., EGLE’s Interim CEO and Board member.

“Christophe’s appointment marks a pivotal moment for EGLE, as we focus on clinical development and advancing our technology platform, his experience, knowledge and networks of the sector will ensure Egle continues to shape its future.” said Michel Detheux, Chairman of the board.

Christophe Quéva, Ph.D.

Dr. Christophe Quéva brings over two decades of experience in immuno-oncology, spanning portfolio development from target identification to clinical trials and regulatory approvals. Before joining Egle, he founded and led Ovie Therapeutics, a company focused on an innovative treatment for brain cancer. Since 2022, he has also served as Chief Scientific Officer at DEM BioPharma, driving the development of cancer macrophage-targeting therapies. Prior to this, Dr. Quéva was Chief Scientific Officer at Oncorus, where he advanced next-generation immunotherapies using oncolytic viruses and RNA therapeutics. He also held the same role at iTeos Therapeutics, overseeing the development of a groundbreaking immuno-oncology portfolio.

Earlier in his career, Dr. Quéva held leadership roles at Gilead Sciences, Amgen, and AstraZeneca, contributing to oncology and inflammation drug discovery. He holds a Ph.D. in Life and Health Sciences from the University of Lille in France and completed postdoctoral research in cancer biology at the Fred Hutchinson Cancer Research Center. Dr. Quéva’s extensive career includes numerous patents and publications in the oncology field, reflecting his commitment to advancing patient care through innovative science and leadership.

About Egle Therapeutics SAS (Egle)

Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a proprietary discovery platform to unveil novel Treg specific targets and to develop innovative Treg-focused drug candidates for oncology and autoimmune diseases. Egle is evaluating its most advanced drug candidate in oncology, EGL-001 (a Treg-selective anti-CTLA4-IL-2m), in a Phase I/II clinical trial. In autoimmunity, Egle has completed IND-enabling studies for, EGL-003 (an IL-2 Treg engager), and is poised to commence a clinical trial in 2025.

Find out more at www.egle-tx.com.

Contacts:
contact@egle-tx.com / +33 (0)1 86 64 08 57
investor.relations@egle-tx.com / +33 (0)1 86 64 08 57

Vancouver, BC, Canada – January 8, 2025 – Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics as a new category in regenerative medicine, today announced that it has closed a US$115 million Series B financing round. The financing was led by Dimension, a multistage investment firm dedicated to the interface of technology and the life sciences, with participation from existing and new investors including Novo Nordisk, Radical Ventures, an undisclosed leading global investment firm, InBC, Pallasite Ventures, Pangaea Ventures, Rhino Ventures, and T1D Fund: A Breakthrough T1D Venture.

This financing builds on Aspect’s recent momentum, including a CA$200 million partnership with the governments of Canada and British Columbia and a partnership with Novo Nordisk focused on diabetes and obesity. Proceeds from the Series B enable Aspect to advance multiple bioprinted tissue therapeutics towards the clinic with a mission to deliver a new class of cellular medicines and functional cures for people living with serious metabolic and endocrine diseases. Additionally, the funds will fuel the expansion of Aspect’s industry-leading, full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials.

“I am incredibly proud of the progress our team is making on our mission to develop disease-modifying treatments for people living with serious diseases,” said Tamer Mohamed, Founder and CEO, Aspect Biosystems. “We are thrilled to partner with Dimension and this exceptional, mission-aligned investor syndicate. We are grateful for their support as we embark on our next chapter dedicated to transforming patient outcomes for the better.”

Concurrent with the financing, Nan Li, Founder & Managing Partner at Dimension, was appointed to the Company’s Board of Directors.

“Aspect is an embodiment of the multi-disciplinary companies that we believe will define the next chapter of biotech,” said Nan Li, Founder & Managing Partner, Dimension. “The company brings together capabilities across tissue engineering, cell therapy, biomaterials, computer vision and robotics to deliver on the promise of regenerative medicine. We are beyond excited to partner with the Aspect team to advance their programs forward and to build a generational company.”

About Aspect Biosystems

Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat some of the most elusive diseases. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body. Aspect is creating these next-generation cell therapies by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials. Aspect is advancing a pipeline of bioprinted tissue therapeutics across multiple disease areas in the endocrine and metabolic space including diabetes, obesity, rare endocrine disorders, and liver disease. Aspect’s pipeline development strategy involves both proprietary programs as well as strategic partnerships, including a collaboration with Novo Nordisk focused on diabetes and obesity. For more information, please visit www.aspectbiosystems.com and follow on LinkedIn.

Contact

Natalie Korenic
Aspect Biosystems
media@aspectbiosystems.com